Financial Performance & Strategic Aspirations - Novo Nordisk achieved sales growth of 18% (CER) in the first six months of 2025, with operating profit growth of 29% (CER)[11] - Obesity care sales reached DKK 38.8 billion, a 58% increase at CER, highlighting the strong performance in this therapeutic area[11] - Rare disease sales increased by 15% at CER, reaching DKK 9.5 billion[11] - The company returned DKK 36.5 billion to shareholders, demonstrating a commitment to attractive capital allocation[11] Market Dynamics & Key Products - In the US, the branded anti-obesity medication market experienced growth exceeding 160%[28] - International Operations saw sales growth of 19%, driven by GLP-1 Diabetes and Obesity care[33] - Total GLP-1 class market share in International Operations reached 71%[36] - Global diabetes and obesity unmet need is significant, with less than 1% of people with obesity globally treated with branded AOMs[44] Research & Development Highlights - Amycretin is advancing to phase 3 development based on successful phase 1b/2a trial results, showing significant body weight loss[49, 53] - Semaglutide 2.4 mg demonstrated a 20% reduction in MACE in the SELECT trial for people with overweight or obesity and established CVD[249]